Work

Diversity in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Lecanemab and Elenbecestat Early Alzheimer’s Disease Studies

Year: 2022

Type: article

Source: Alzheimer s & Dementia

DOI: 10.1002/alz.069198

Authors: Joshua Grill, Doris P. Molina‐Henry, Reisa A. Sperling, Shobha Dhadda, Kate Tranotti, Russell Harris, Theresa Devins, Chad J Swanson, Michio Kanekiyo, Michelle Gee, Michael C Irizarry, Lynn D Kramer, Paul Aisen, Rema Raman

Institutions: University of California, Irvine, University of Southern California, Harvard University, Massachusetts General Hospital, Eisai (United States), Eisai (United Kingdom)

Language: English

Topic: Ethics in Clinical Research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDGs: Good health and well-being, Reduced inequalities

Open Access status: closed

OpenAlex ID: W4312086184

FWCI: 0.441

Cites:

Cited by: 2

Related to: 10